MPO and vasculitis: Assessments using Birmingham Vasculitis Activity Score and myeloperoxidase (MPO)‐ANCA assays showed that seven of the nine patients responded to TCZ treatment, and no recurrence was observed in six of these seven patients after TCZ treatment cessation (Figure 1a).